NCGS, Inc.

Nanotherapeutics is a privately-held emerging biopharmaceutical company with both proprietary platform technologies and a diversified pipeline of products. The Company has expertise in pre-clinical and clinical development, formulation optimization, and cGMP manufacturing of biopharmaceutical products and medical devices. The Company's proprietary platform technologies can be used with all drug types, ranging from small molecules to proteins and vaccines.

Many of our diversified products have multiple indications ("dual-use"​) with potential in the areas of infectious diseases, CNS, oncology, vaccines, and biodefense. Over the past several years, we have focused our efforts on meeting the US government’s interests to develop safe, effective medical countermeasures against certain biological and radiological threats.

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA.
ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital.

- 25 years experience and 2500 customers worldwide
- Premium R&D CRO based in USA with global reach
- Seasoned project managers
- Extensive Academic partnerships
- Flexible business models
- Competitive pricing options
- Industry's largest ever-greening stock compound inventory
- Ongoing investments in novel proprietary chemistry and discovery platforms

One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

MedSource, now part of Ergomed, is an award-winning clinical research organization (CRO) that delivers high-quality clinical trials through strong relationships and specializes in oncology, neurology/CNS, and infectious diseases. We have participated in 795+ clinical trials globally; more than 250 of them have been in oncology. Our efforts support biopharmaceutical clients who conduct complex clinical trials in the most challenging disease states and patient populations. Our wide experience encompasses a range of therapeutic areas, product types, clinical trial phases and study designs.

As trusted advisers and leaders in the industry, we know that strong relationships lead to strong results. While our services have expanded through the years, we’ve always kept our clients, employees and trial subjects a priority. With their needs in mind, we match a flexible process with transparency at every step along the way. Our goal is for our clients to return to MedSource whenever they need high-quality clinical trial support, because they know we will always act with their best interests in mind.

Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies.

In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 50,000 staff across a network of more than 900 independent companies in over 50 countries, operating more than 800 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing.

Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ sales have increased by 35% each year (in compound average) to over EUR 4.5 billion in 2019.